NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Wednesday that its fourth quarter revenues rose 6 percent, largely due to a 13 percent uptick in its clinical labs segment driven by increased sales of its molecular diagnostics tests.

For the three months ended July 31, the company reported total revenues of $28.2 million, up from $26.6 million a year earlier.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.